Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a key milestone in its ongoing imaging study for multiple sclerosis (MS), with patient enrollment hitting the halfway mark and early data showing a promising signal in MS lesions. The company announced the progress as part of its collaboration with Massachusetts General Hospital, where researchers are evaluating a novel positron emission tomography (PET) imaging tracer that could support the development of Lucid-MS, Quantum BioPharma’s MS drug candidate.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person’s life. The study is evaluating a technique that allows researchers to distinguish between nerve damage that may still be reversible and damage that is permanent, which could be critical for treatment decisions.
The imaging tracer is designed to bind to a protein called myelin, which is damaged in MS. By tracking myelin loss and repair, the tracer could provide a more precise measure of disease activity and progression than current methods. Early imaging data showed a meaningful signal in MS lesions, suggesting the tracer may effectively visualize myelin damage. This could help researchers assess whether Lucid-MS, which aims to promote myelin repair, is working as intended.
“Reaching the halfway mark in patient enrollment is an important step forward for this study,” said a spokesperson for Quantum BioPharma. “The early imaging data is encouraging and supports the potential of this novel tracer to provide valuable insights into MS pathology.” The company noted that the study is expected to complete enrollment in the coming months, with final results to be reported thereafter.
If successful, the imaging tracer could become a tool for monitoring treatment response in clinical trials and ultimately in clinical practice. This would address a significant unmet need in MS care, where current imaging techniques often fail to capture the full extent of nerve damage or repair. The development also highlights the potential of PET imaging to advance precision medicine in neurology.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. The company’s stock is traded on NASDAQ under the symbol QNTM and on the Canadian Securities Exchange under QNTM. More information is available in the company’s newsroom at https://nnw.fm/QNTM.
